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Abstract
High throughput (HT) screening is at the starting point for most drug discovery pro-
grams. As the range of targets being pursued widens new technologies have to be 
deployed to enable assays built to measure the activity of proteins previously deemed 
challenging. Flow cytometry is a technology providing multi-parametric analysis of 
single cells or other particles in suspension, such as beads. High throughput (HT) flow 
cytometry has become a very attractive screening platform for drug discovery. In this 
chapter we describe a 1536 well format high throughput screen of 500,000 compounds 
to find inhibitors of Rac1 GTPase to prevent allergic airway hyper-responsiveness in 
asthma. We discuss the assay development, miniaturization and validation carried out 
prior to the full screening campaign. We then describe how we have automated our 
iQue® HD screener instruments and how we proceed with the data analysis and explain 
why we chose to run this screen on a flow cytometer and how it enabled us to reduce cost 
and timelines for the project.
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1. Introduction
Asthma is a heterogeneous inflammatory disorder of the airways characterized by chronic 
deregulated inflammation, bronchial hyperreactivity, and symptoms of recurrent wheezing, 
coughing, and shortness of breath. Its prevalence has increased considerably over the past 
three decades, particularly in Western countries. Asthma is a major public health problem 
that affects 300 million people worldwide [1, 2].
© 2018 The Author(s). Licensee IntechOpen. This chapter is distributed under the t rms of the Crea ive
Comm ns Attribution Lic nse (http://creativecommons.org/licenses/by/3.0), which permits unrestricted use,
distribution, and reproduction in any medium, provided the original work is properly cited.
Airway hyperresponsiveness (AHR), one of the hallmarks of asthma, directly results from 
excessive contraction of airway smooth muscle cells (aSMC). The degree of AHR always cor-
relates with asthma severity and the need for therapy [3, 4]. Regular treatment of chronic 
asthma consists of a combination of inhaled anti-inflammatory corticosteroids and long-acting 
beta2-adrenergic receptor agonists for bronchodilation. However, severe asthma escapes to 
usual treatments or frequently requires higher doses. In acute asthma, short-acting beta2 ago-
nists or anticholinergics are used as bronchodilators. These drugs are rapidly effective but 
can be insufficient in some cases of severe acute asthma attack. Despite available therapies, 
many patients with severe asthma remain uncontrolled and the number of asthma deaths is 
still elevated [5]. There is thus an obvious need for new drugs acting through other pathways 
to prevent or reverse AHR and decrease severe asthma attacks, hospitalizations and deaths.
The molecular mechanisms regulating aSMC contraction and proliferation involved in AHR 
are still largely unknown. Understanding the intracellular signaling pathways responsible for 
AHR is thus essential to identify new targets and design new treatments. In this way, the Rho 
protein Rac1 has been identified as a promising candidate.
The Rho/Rac proteins constitute a family of small GTPases of more than 25 members in mam-
mals. So far, the best characterized members of this family include the members of the Rho 
(RhoA, RhoB, RhoC), Rac (Rac1, Rac2, RhoG), and Cdc42 (Cdc42) subfamilies. Rho/Rac pro-
teins share a common structure (40–95% identity) composed of a six-stranded mixed β sheet 
flanked by five α helices. The core G domain is made up of five polypeptide loops (G1–G5) 
involved in nucleotide, regulators and effectors interactions. Like the majority of Ras super-
family GTPases, most members of the Rho/Rac family behave as molecular switches that cycle 
between inactive (GDP-bound) and active (GTP-bound) states. In basal conditions, these pro-
teins are inactive and sequestered in the cytosol due to their binding to Rho GDP dissociation 
inhibitors (RhoGDIs). Upon cell stimulation, Rho proteins became GTP-bound, translocate 
to the plasma membrane after release from RhoGDI, and interact with their primary effector 
molecules to trigger different signal transduction pathways. In addition to RhoGDIs, the acti-
vation/inactivation cycle of Rho/Rac proteins is regulated by a complex set of regulatory pro-
teins that include GDP/GTP exchange factors (GEFs) and GTPase activating protein (GAPs) 
(Figure 1). Interaction of Rho/Rac protein with a GEF promotes the exchange of GDP for GTP 
molecules, thus leading to the rapid activation of Rho/Rac proteins during cell stimulation 
events. By contrast, GAPs promote the hydrolysis of the bound GTP molecules to GDP, thus 
allowing the transfer of the GTPases back to the inactive state at the end of the stimulation 
cycle [6].
During the last decade, Rho/Rac protein signaling pathways have been recognized as major 
regulators of essential cellular functions. Rac1 is a key regulator of cytoskeletal structure and 
dynamics, leading to lamellipodia and ruffle formations [6, 7]. Thanks to this last function, 
Rac1 controls cellular migration and adhesion. Recently, we demonstrated that Rac1 regulates 
vascular SMC contraction, and consequently modulates arterial pressure [8]. Accordingly, we 
hypothesized that Rac1 could also be involved in aSMC contraction. We demonstrated that 
the specific SMC deletion of Rac1 (SM-Rac1-KO) in mice prevents bronchoconstriction ex and 
in vivo. Our results showed that the decreased expression or activity of Rac1 in aSMC impairs 
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agonist-induced rise in intracellular Ca2+ concentration through a mechanism involving Rac1-
dependant control of PLC activity. Interestingly, Rac1 deficiency has no impact on the respira-
tory system in basal, physiological condition. However, deletion of Rac1 expression in aSMC 
or nebulization of the Rac inhibitor NSC23766 prevented AHR in an allergic asthma model 
in mouse. These data indicate that (1) Rac1 is a critical component in aSMC contraction and 
(2) inhibition of Rac1 activity or expression may represent a novel therapeutic approach for 
patients with airway AHR such as asthma.
Unfortunately, the currently available drugs that inhibit Rac1 (EHT 1864 and NSC23766) have 
low affinity and induce critical off-target effects, thus highlighting the obvious need to dis-
cover new Rac inhibitors [9, 10].
In this chapter we describe how a published flow cytometry assay was taken and converted 
to a 1536 well format suitable for high throughput screening (HTS) to enable the screening 
of 500,000 compounds in the AstraZeneca Global HTS Centre to attempt to find new Rac1 
inhibitors. We describe the whole protocol from receiving assay ready plates through to the 
data analysis and discuss the criteria that are important for an assay to be suitable for a high 
throughput screen by flow cytometry and describe the validation process we go through prior 
to starting a high throughput screening campaign.
Figure 1. Activation cycle of Rho/Rac proteins and their regulatory proteins. Activation of Rho/Rac proteins is mediated 
by a guanine nucleotide exchange factor (GEF) leading to GTP loading and to the translocation of Rho/Rac proteins to 
the plasmatic membrane. This active configuration of Rho/Rac proteins promotes effector interactions. To “turn off” the 
cycle, a GTPase-activating protein (GAP) accelerates the intrinsic GTPase activity of Rac, allowing Rac to return to its 
inactive state in the cytosol. The guanine nucleotide-dissociation inhibitor (GDI) binds specifically to GDP-bound Rho/
Rac proteins, prolonging the inactive state and sequestering the GTPase in the cytosol.
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2. Assay development
Several papers have demonstrated the utility of a bead-based flow cytometric GTP-binding 
assay for screening GTPase targets for small molecule inhibitors in both singleplex and mul-
tiplex formats [11–13]. As part of AstraZeneca’s Open Innovation initiative, we collaborated 
with researchers at l’Institut du thorax to identify small molecule inhibitors of Rac1 GTPase. 
We therefore set out to develop a bead-based assay for screening Rac1 in a singleplex fash-
ion (Figure 2) for a screening campaign in 1536 well plates on an iQue® Screener HD. The 
Intellicyt iQue® Screener HD is a flow cytometer with an autosampler able to sample from 96, 
384 and 1536 well plates. Using proprietary technology the instrument separates well samples 
with an air bubble allowing the software to determine what sample comes from what well 
making the instrument a true high throughput instrument.
The assay is based on glutathione-coated beads used to capture GST-tagged Rac1. Bodipy-
labeled GTP (FL-GTP, ThermoFisher Scientific), is then used as a tracer for the detection of 
compounds that compete with its binding to the GTPase resulting in a decreased fluorescence 
signal.
We purchased commercially-available glutathione coated particles (GSH beads, size 4.0–
4.9 μm, Spherotech) that have glutathione covalently coupled to their surface and glutathione 
S-transferase tagged Rac1 protein (human wild type) (GST-Rac1, ThermoFisher Scientific) 
and bound the GST-Rac1 onto the GSH beads overnight. Assay development was performed 
in 384 well plates before miniaturizing the assay for 1536 well plates. We optimized the con-
centration of FL-GTP to use in the assay to achieve the largest signal to background window 
and also confirmed that FL-GTP did not bind to unconjugated beads to demonstrate Rac1/
GTP binding specificity. Based on the data shown in Figure 3 and associated table, 100 nM 
FL-GTP was selected.
To validate that the beads were coated with GST-Rac1 and that they would bind bodipy-labeled 
GTP the prepared beads were mixed with serial dilutions of unlabeled GTP (ThermoFisher 
Figure 2. Pictorial representation of GST-Rac1 bound to GSH beads. Inhibitors of fluorescent GTP binding result in 
decreased FL1-H signal.
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Scientific) as a competitor followed by the addition of FL-GTP. To prepare the assay, 5 μL of 
coated beads were dispensed into wells on a 384 well plate followed by 5 μL of buffer containing 
unlabeled GTP in serial dilutions in triplicate, then 5 μL of 100 nM FL-GTP was added for a final 
volume of 15 μL and incubated for 30 min. The methods described in Refs. [11–13] included a 
final incubation for up to 60 min at 4°C. We wanted to be able to prepare and incubate the plates 
at room temperature (RT) for large scale screening, so we incubated plates both at 4°C or RT and 
then read the plates on the iQue Screener HD immediately after incubation or after 2 h at RT to 
determine if the signal window was still adequate for screening at that time. The beads are not 
fluorescently labeled, therefore exhibit low fluorescence intensity in the FL-1 channel (excita-
tion 488 nm; emission filter 530/30 nm). Beads with bound FL-GTP exhibit a marked increase in 
fluorescence (approximately 200–500 fold). Inhibitors of GTP binding decrease the FL-1 fluores-
cence which is the measured signal for the samples read on the iQue® Screener HD. For analysis, 
beads were gated on forward scatter height (FSC-H) vs. side scatter height (SSC-H), then dou-
blets were excluded by gating on the singlet population on forward scatter height vs. forward 
scatter area (FSC-A). Figure 4 shows representative data for the gating scheme and the decrease 
in bead fluorescence with three concentration response curves (0–333.3 μM unlabeled GTP).
Figure 3. Optimization of FL-GTP concentration and confirmation of binding specificity. (A) Unconjugated or Rac1-
coated beads were incubated with varying amounts of FL-GTP in the presence or absence of 0.5 mM unlabeled GTP and 
bead fluorescence measured on the iQue®. : Rac1 coated beads in the presence of 0.5 mM unlabeled GTP, : bare beads, 
and : Rac1 coated beads. (B) Signal to background table for each concentration of FL-GTP.
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Addition of unlabeled GTP was able to compete with FL-GTP under all assay conditions in a 
concentration-dependent manner (Figure 5). Samples incubated at 4°C and read immediately 
afterward showed the highest binding of FL-GTP as well as the greatest decrease in fluo-
rescence in the presence of unlabeled GTP. All other conditions showed a slight increase in 
FL-GTP intensity, but very similar competition curves. Assay Z′ was greater than 0.75 for all 
conditions. These data in a final volume of 15 μL demonstrated that the assay was adequate 
to move forward with miniaturization, so the assay was tested again in small volumes using 
2 μL of GST-Rac1 coated beads, 2 μL of buffer containing unlabeled GTP in serial dilutions, 
and 2 μL of FL-GTP for a total assay volume of 6 μL in low volume 384 well plates. The minia-
turized assay was comparable to the preliminary tests (data not shown) so we moved forward 
with miniaturization to 1536 well plates.
The challenge for us was to perform the assay in a 1536-well format in order to minimize both 
cost and timelines of the screen.
Miniaturization to 1536 well format was first performed by using blank GSH beads to test dis-
pensing, inter-well shake speeds, and sip times. Runs were repeated under various conditions 
Figure 4. Gating scheme for Rac1 assay. (A) Beads gated on FSC-H versus SSC-H, (B) then on FSC-H versus FSC-A for 
singlet beads, (C) time-resolved serial dilution curves (time versus log(Median FL1-H fluorescence) of singlet beads. 
Wells treated with 0–333.3 μM unlabeled GTP show decreasing FL-GTP bound to beads (data in triplicate).
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to determine the optimum protocol. During these runs it was determined that it was best to use 
the bead sample buffer 0.1% (w/v) BSA in NP-HPS (30 mM HEPES pH 7.2, 100 mM KCl, 20 mM 
NaCl, 0.01% NP-40) supplemented with 1 mM DTT to prime the system before acquisition and 
during inter-well shaking. We found that we could decrease the sip time during which the sam-
ple probe aspirates from the well to 0.5 s per well, resulting in the acquisition of an entire 1536 
well plate in under 50 min. Once the iQue® Screener HD protocol was optimized with blank 
GSH beads, we ran 3 separate plates with ½ of the plate with negative control (sample buffer) 
and ½ of the plate with positive control (unlabeled GTP). Briefly, the assay was performed by 
dispensing 2 μL of GST-Rac1 coated beads to each well of a 1536 well plate, followed by either 
2 μL of sample buffer (negative control) or 2 μL of 500 μM unlabeled GTP (positive control; 
final concentration 166.7 μM). Finally, 2 μL FL-GTP was added to each well, then the plate was 
heat sealed with a pierceable foil seal and incubated at RT for 30 min. Each plate’s Z′ factor was 
calculated as greater than 0.5 with an average of 0.68 across the three plates (Figure 6).
We optimized the coating of Rac1 on the beads by testing the signal strength and assay window 
achieved over a 15 fold range of initial protein concentration from saturation down to zero (Table 1).
The aim was to identify the optimum concentration to use while maintaining best signal to 
background ratio. Following optimization i.e. check that the assay was suitable for running 
Figure 5. Comparison of incubation on competition of FL-GTP. Bead fluorescence measured by competition of FL-GTP 
by unlabeled GTP. GST-Rac1 coated beads with FL-GTP were incubated in the presence of varying amounts of unlabeled 
GTP in triplicate. Dotted lines indicate bead fluorescence in the presence of no unlabeled GTP. : incubated at 4°C for 
30 min, : incubated at RT for 30 min, : incubated at 4°C for 30 min then stored for 2 h at RT and : incubated at RT for 
30 min then stored for 2 h at RT.
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Rac1 concentration (μM) Max signal Min signal Z′ S/B
5 107,304 15,623 0.57 6.87
2.5 106,718 14,885 0.82 7.17
1.25 66,630 8559 0.79 7.79
0.625 39,836 5630 0.60 7.08
0.3175 21,087 3518 0.24 5.99
Table 1. Optimization of bead coating. Beads were coated with various concentrations of Rac1, incubated with FL-GTP 
and the bead fluorescence measured on the iQue®. Max refers to signal in the absence of 0.5 mM unlabeled GTP, min 
refers to signal in the presence of 0.5 mM unlabeled GTP.
Figure 6. Representative data from 1536 well Rac1 assay. (A) Beads gated on FSC-H versus SSC-H, (B) then on FSC-H 
versus FSC-A for singlet beads, (C) time-resolved data (time versus log(Median FL1-H fluorescence) of singlet beads. 
Wells treated with 0 or 166.7 μM unlabeled GTP show decreasing FL-GTP bound to beads.
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at large scale, the assay was validated by running a set of 7000 core compounds and a set 
of 3000 low molecular weight compounds (LMW) (mol.wt. below 325) (see Section 3) on 2 
separate occasions to assess variability. These compounds encompass the diversity of the col-
lections that will be screened. Running an HTS campaign is a costly and fairly demanding 
process. For this reason we need to ensure an assay is robust (Z′ factor greater than 0.5, sig-
nal to background greater than 3, low coefficient of variation across whole plate) and repro-
ducible i.e. active compounds will be found repeatedly if the assay was run multiple times. 
We therefore defined a set of criteria we need to satisfy prior to embarking on a screen [14]. 
Core compounds were run at 12.5 μM and LMW at 100 μM. We use an in-house designed 
Tibco Spotfire® tool to analyze the data and visualize the repeatability of the assay. Validation 
showed the assay was performing well resulting in good agreement between the repeat runs 
as depicted in Figure 7 which shows a Bland-Altman plot comparing data from the 2 runs; 
the average difference is 0.3 and the standard deviation of the difference around 7%. We were 
confident that this assay was now amenable to full scale screening.
3. Screening
The iQue® Screener HD increases the capabilities of flow cytometry with rapid sampling 
and assay miniaturization with a final assay volume of 6 μL per well, using as little as 1 μL 
per sample with no dead volume. The iQue® Screener HD has an autosampler that delivers 
samples in an air gap delimited stream to the cytometer engine. The plate loading area is 
accessible to robotic integration and an easy to use interface allows integration of labora-
tory automation. The entire plate of data is processed at one time. ForeCyt® software that 
controls the iQue® Screener HD allows plate level annotation, analysis, and visualization of 
the acquired data, enabling rapid, high content, multiplexed analysis of cells and beads in 
suspension. To enable the throughput required, we have linked two iQue® Screener HD to an 
Figure 7. Bland-Altman plot of validation data.
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ACell benchtop automation system (HighRes Biosolutions), as shown in Figure 8, compris-
ing a Nanoserve plate carousel and an ambient nest integrated by the Cellario® scheduling 
software. This simple small footprint automation system allows unattended operation as well 
as automatically clean the cytometers at the end of each run and has a capacity of up to 28 
plates per working day. We also used a third iQue® Screener HD as a standalone instrument 
for backup and additional throughput.
Prior to first use, a daily clean was run on the iQue® consisting of 5 min in decontamination 
solution (Intellicyt), a mildly basic solution, followed by 5 min in cleaning solution (Intellicyt), 
a mildly acidic and surfactant solution that neutralizes the decontamination solution and a 
final 10 min in water. This ensures cleaning of the entire fluidics path from probe to detector. 
Following this procedure a QC test was run to check the performance of the iQue instruments 
consisting of a 2 min water test to check cleanliness of the system followed by an 8 peak 
(Intellicyt) and 6 peak (Intellicyt) beads test to check laser alignment and performance of the 4 
fluorescence channels. The 8 peak product contains a mixture of several similar size particles 
with 8 different fluorescence intensities. Every particle contains a mixture of fluorophores that 
enables their excitation with the blue laser (488 nm) to validate the FL1, FL2 and FL3 chan-
nels of the iQue. Similarly, the 6 peak product contains a mixture of particles with 6 different 
fluorescence intensities excitable by the red laser to validate the FL4 channel.
All compounds for HTS in AstraZeneca are delivered in what are known as assay ready plates. 
Assay ready plates have the correct volume of compound in them such that on addition of 
Figure 8. Automation platform used with our iQue® Screener HD. (A) and (B) iQue® Screener HD, (C) ACell robotic arm, 
(D) NanoServe™ stacker carousel.
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the assay reagents the correct final compound concentration is achieved. Compound volumes 
are in the nL range and are added by a Labcyte Echo® acoustic dispenser. Using assay ready 
plates removes the need for intermediate dilution steps to get compounds and vehicle to the 
correct concentration making plate processing much simpler and faster in HTS screens.
Within the AstraZeneca HTS Centre we have 2 main collections of compounds that we screen. 
We have what we call the core collection that is screened at a single final concentration of 
10 μM or a concentration close to this balancing solubility of the compounds with detecting 
weaker activity. We also have a low molecular weight collection [15] where we have sepa-
rated out compounds with molecular weights below 325 Da that pass solubility filters. These 
compounds are screened at higher concentrations (typically 100 μM) to ensure we detect the 
activity of these compounds that potentially have better ligand efficiencies than hits that may 
be found in the core collection.
Rac1-coated beads were prepared by vigorously vortexing the glutathione beads, then trans-
ferring 7 mL into a 50 mL centrifuge tube. The beads were centrifuged (1000 × g, 5 min) and 
the supernatant removed, taking care not to disturb the pellet. 7 mL of wash buffer (0.1%, 
w/v BSA in NP-HPS) were added and vortexed vigorously to wash the beads. Beads were 
then incubated at room temperature for 30 min. Lyophilized Rac1 protein was reconstituted 
to 0.25 mg/mL final concentration (~5 μM) by adding 25 μL of wash buffer and mixing gen-
tly until the protein is completely dissolved. After the 30 min incubation of the beads they 
were pelleted by centrifugation (1000 × g, 5 min) and the supernatant discarded, taking care 
not to disturb the pellet. Beads were resuspended in 700 μL of wash buffer +175 μL of Rac1 
protein to a final concentration of 1 μM. The sample was vortex mixed gently and incubated 
overnight at 4°C. After incubation at 4°C, beads were washed twice with 14 mL sample buffer 
(wash buffer +1 mM DTT) pelleted by centrifugation (1000 × g, 5mins) between washes and 
finally resuspended in 14 mL wash buffer. Labeled beads were stored at 4°C. An accurate 
bead count was made using the iQue® Screener HD with beads diluted to a density of 1.33 × 
106 beads/mL prior to running the assay. The method described here should provide enough 
beads for 16 plates a day for 6 days.
The primary screen was performed at compound concentration of 12.5 μM (100 μM for LMW) 
against a diversity collection of 500,000 compounds. All assay ready plates of compounds 
were prepared by our compound management team. The plate layout included on-board 
controls in the four central columns (64 wells of either 12.5 μM unlabeled GTP or 1% (v/v) 
DMSO as inhibitor and neutral controls, respectively). Each remaining well contained a single 
compound from the library, resulting in single shot screening of 1408 compounds per plate.
To assemble the assay, the Rac1-coated beads were vigorously vortexed to mix and dispensed 
3 μL/well to each well of the 1536 well assay ready plate (polypropylene deep well V-bottom 
microplates, Greiner Bio-One) using a Multidrop™ dispenser and a small tube cassette. Assay 
ready plates for this assay had 7.5 nL (60 nL for low molecular weight compounds) of a 10 mM 
stock of compound dispensed to each well. 3 μL/well of 200 nM Bodipy-FL GTP in sample buf-
fer was added and plates were centrifuged (250–500 × g, 10 s) to ensure that samples are at the 
bottom of the plate and not adhered to the walls of the wells. Plates were sealed using a pierce-
able heat seal (recommend Thermo Cat No AB-1720 or equivalent) and incubated for 120 min 
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at room temperature shielded from light. Samples were acquired on the iQue® HD Screener 
using the “Rac1 template” acquisition and analysis template. Rac1 Sample Buffer (0.1% BSA in 
NP-HPS supplemented with 1 mM DTT) in the iQue HD Buffer station gave the best sampling 
results. The cytometer protocol was set up with 0.6 s sip time, 0 s up time, standard pump 
speed, and medium detector speed as can be seen in Figure 9. Reading time per plate is 45 min.
In the Intellicyt ForeCyt® software, we acquired flow cytometric light scatter as well as fluo-
rescence emission in the FL1 channel (Ex 488 nm, Em 530 ± 30 nm). We gated on forward 
scatter and side scatter to identify the bead populations followed by forward scatter area 
vs. height to identify the singlet bead subpopulation. The median fluorescence of the singlet 
bead population was then extracted. Data files were exported from the ForeCyt® software as 
multiple plates in 1536 grid format as a comma-delimited text file. The files were manually 
imported into Genedata Screener® for analysis.
Data were normalized on a plate by plate basis using the on-board controls to calculate a 
% effect value and by robust Z Score. Robust Z Score is a derivation of the original Z Score 
calculation [16] substituting median for average and robust standard deviation for standard 
deviation and is used routinely for normalization and hit calling in the AstraZeneca HTS 
Centre alongside the more common 2-point normalizations using positive (inhibitor) and 
negative (neutral) control wells. By using robust statistical measures the calculation is resis-
tant to outliers which are, of course, the hits in an HTS which can be missed if using the 
Figure 9. ForeCyt® protocol on iQue® Screener HD.
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non-robust version of the equation. Robust Z Score is calculated according to the equation 
below (Eq. (1)) and normalizes individual wells by calculating the number of robust standard 
deviations the well value is away for the median of the plate central reference. In most HTS 
screens this central reference is the median of all the compound wells on a plate as >99% of 
the wells will be inactive and will define the central reference.
  N ( x )  =  x − 〈CR〉 _______
〈〈CR〉〉
 (1)
x is the measured raw signal value of a well;  〈CR〉 is the median of the measured signal values 
for the central reference values on a plate;   〈〈CR〉〉 is the robust standard deviation of the mea-
sured signal values for the central reference values on a plate.
Hits were identified using a cut-off of −10 in robust Z score; this corresponded to an approxi-
mate change of fluorescence greater than 30% (50% for LMW) from controls.
The primary screen of 500,000 compounds took 4 weeks to complete and some summaries of 
the data are presented in Figure 10.
Figure 10. Primary screen data. (A) Distribution plot, (B) box plot, (C) plate view in Genedata Screener® and (D) assay 
overview in Genedata Screener®.
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Figure 11. Primary screen data analysis plots. (A) Number of compounds analyzed per run and (B) hit rate per run.
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The screen ran at a throughput of 20 plates per day equivalent to 31,000 compounds per day. The 
overall distribution in Figure 10 shows a narrow central peak centered on zero with the left tail 
containing potential hits. This is a typical distribution shape seen in HTS screens and clearly shows 
that the assay was capable of identifying hits. The box plots shows the stability and consistency of 
the assay and tightness of the data across multiple plates and also allows visualization of the hits 
represented as the outliers on the plot. A typical plate analysis is shown depicting the controls in 
the central columns and a few hits scattered across the plate as dark blue wells with the histogram 
showing the heat map scale of the robust Z score. The assay overview (Figure 11) shows the whole 
set of plates (with the low molecular weight collection highlighted) run on one iQue® Screener 
HD highlighting the hit rate variation with the collection subset. It can be clearly seen that the hit 
rate in the low molecular weight set, found in the first 32 plates, is elevated above that of the core 
collections. This can occur due to the higher screening concentration leading to more non-specific 
inhibition due to common contaminants such as metals which are then ruled out by further down-
stream assays and SAR analysis Although not shown, the assay signal to background as well as 
Z′ factor [17] are monitored throughout the screen as markers of data quality and again indicated 
that this assay was of high quality.
5870 hits were identified after the primary screen representing a 1.2% overall hit rate. All 
hits were then tested as 10-point concentration responses (100–0.003 μM) against Rac1 as 
well as RhoA and CDC42 so we could assess selectivity of the compounds for Rac1. The 
assay is performed as described for the primary screen. All hits identified in the primary 
Figure 12. Representative curves of selective and non-selective compounds.
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screen were serially diluted 1:3 to construct a 10-point concentration response curve. 
Compound concentration curves are dispensed using acoustic dispensing into assay ready 
plates at 150 compound curves per plate. Wells are backfilled with DMSO to keep the 
DMSO concentration constant in all wells. The plates were sealed and stored in the con-
trolled atmosphere and temperature working plate store before use as for primary screen 
plates. 1 mM MgCl
2
 was added to the buffer for the RhoA assay. 82% of the tested com-
pounds were confirmed as active with 44 identified as Rac1 selective using a ≥10 fold ratio 
of Rac1 IC
50
 vs. RhoA and Cdc42 as a cutoff. These compounds encompass a variety of 
chemical structures. Figure 12 shows representative curves of selective and non-selective 
compounds. Selected hits are being further characterized through a panel of cellular assays 
by the team at INSERM.
4. Conclusions
Until recently flow cytometry was considered a powerful technology dedicated to bespoke 
assays where just a few samples were to be measured. No medium throughput let alone high 
throughput screen could be run on this technology due to lack of plate handling features, time 
needed per sample and therefore cellular imaging was the preferred method for any high 
content screen. Increases of interest in phenotypic screening combined with a desire to access 
relevant cell models, often suspension cells, and development of plate-based sampling flow 
cytometers have led to the opportunity to use flow cytometry as a drug screening technology 
platform. The ability to perform multiplexing where different cells or particles labeled with 
distinct fluorophores are analyzed in parallel and multiple endpoints are measured leads to 
in-depth analysis of subpopulations within a sample. Such an approach results in increased 
productivity by decreasing timelines and cell requirements, two critical parameters for high 
throughput screening.
We chose to run a screen for Rac1 inhibitors on our iQue® Screener HD as it enabled us to 
miniaturize and run a simple and robust assay on one of our automation platforms.
We have run a successful 500,000 compound screen using the iQue® HD screener as summa-
rized in Figure 13. By optimizing the protocol, we were able to retain high-quality data while 
decreasing read time per 1536 well plate to under 50 min. This allowed us to run the primary 
screen within 4 weeks. Although time is not the most critical criteria we consider it remains an 
important factor as we need to maintain the overall flow of projects through our portfolio and 
therefore we must decide on a suitable time frame for completion of each screen.
High throughput screening is a key method for the identification of hit and lead compounds 
and remains at the start of most of our drug discovery programs. As we pursue a wide range 
of targets we also use a wide range of assays and technologies. We have invested into several 
iQue® Screener systems as we updated and replaced previous detection systems and to fill 
a capability gap for screening suspension cells or primary cells in small sample volumes. 
We have successfully used the iQue® Screener systems in a variety of applications from phe-
notypic screening to more complex multiplex profiling. The technology has enabled several 
projects due to the ability to reduce cell requirement, cost and timelines.
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The screen we have described here would have not been possible a few years ago but, thanks 
to the development of high throughput capable instruments, flow cytometry has found its 
place within the drug discovery process and high throughput screening in AstraZeneca. 
Although we decided not to multiplex our concentration response assays, it should be noted 
that the use of flow cytometry technology does allow for such multiplexing and indeed has 
been described in the literature [12].
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Figure 13. Screen summary.
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